The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|March 26, 2019
MaSTherCell Announces New Commercial Manufacturing Facility for Cell and Gene Therapies
Author(s)Pharmaceutical Technology Editors
Belgium-based CDMO MaSTherCell will expand its European manufacturing capacity for cell and gene therapy products by setting up a new facility in Belgium.
Advertisement
MaSTherCell SA, a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated contract development and manufacturing organization (CDMO), announced in a March 26, 2019 press release that it has signed a lease agreement for a 5700-m2(61,354-ft2) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021.
This new site will expand the company’s current European manufacturing capacity. The facility will include industry 4.0 precepts such as software integration, intelligent equipment, and integrated processes. MaSTherCell will continue to use its existing site for both industrialization and early to mid-stage clinical programs.
“MaSTherCell has a role to play in solving the current lack of commercial manufacturing capacities in Europe, and we believe this facility will be a game changer for market access worldwide,” said Dr. Denis Bedoret, CEO of MaSTherCell SA and president of Masthercell Global, in the press release.
Setting up the new plant in the Gosselies Biopark will keep the production close to its current site. The plant will create several hundred jobs, said Eric Mathieu, chief of operations of MaStherCell SA, in the press release.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement